A Phase 2 interventional study of VR Driving in Traumatic Brain Injury, sponsored by National Institutes of Health Clinical Center (CC). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-14.
Sponsored by National Institutes of Health Clinical Center (CC) · Phase 2, Interventional, and Treatment
Background:
Objective:
Eligibility:
Design:
OBJECTIVE:
The primary objective of this study is to evaluate the NeuroDRIVE behavioral intervention for enhancement of driving abilities, cognitive abilities, and neurobehavioral symptoms after traumatic brain injury (TBI). For the purposes of this protocol, NeuroDRIVE refers to the novel combined approach of driving training and cognitive rehabilitation in a virtual reality environment. While NeuroDRIVE utilizes the VR system as the method through which the intervention is administered, NeuroDRIVE is not the VR system itself.
STUDY POPULATION:
30 adult patients with a history of mild TBI and 30 adult patients with a history of moderate-to-severe TBI. Participants will be recruited from the National Institutes of Health (NIH), WRNMMC, and the broader community.
DESIGN:
The current study is a Clinical Trial Phase II interventional research study. The primary purpose of the study is for treatment, and it will employ a parallel intervention model. There will be no masking (i.e., open label). Participants will be classified into two groups by TBI severity: those with history of mild TBI and those with history of moderate-tosevere TBI. These different severities are known to have distinct cognitive sequelae. Within each severity group, participants will be in a 2 (pre-post) x 2 (treatment vs. wait list) experimental design.
OUTCOME MEASURES:
Primary outcome measures will include:
WAIS-IV or WMS-IV Digit Span subtest
WAIS-IV Digit-Symbol Coding subtest
Secondary outcome measures will include:
-Neuroimaging results:
Regions of Interest for FMRI: Bilateral dorsolateral prefrontal cortex
Regions of Interest for DTI: Corpus callosum, bilateral frontal white matter horns, and bilateral longitudinal fasciculi
-Total scores on the following symptom questionnaires:
Glasgow Outcome Scale-Extended (GOS-E)
Ohio State University TBI Identification Method
Brief Symptom Inventory- 18
Satisfaction with Life Scale (SWLS)
PTSD Checklist- Civilian (PCL-C)
SF-36v2 Health Survey (SF-36v2)
Fatigue Severity Scale (FSS)
Epworth Sleepiness Scale (ESS)
Beck Depression Inventory-II (BDI-II)
Combat Exposure Scale (CES)
Dual Dangerous Driving Index (DDDI)
-Standard and scaled scores from the following cognitive phenotyping assessments (from the TBI Common Data Elements identified by NINDS):
California Verbal Learning Test- Second Edition (CVLT-II)
WAIS-IV Symbol Search subtest
Medical Symptom Validity Test (MSVT)
-Standard and scaled scores from the following additional cognitive phenotyping assessments:
Trail Making Test (TMT)
Test of Premorbid Functioning (ToPF)
Grooved Pegboard
Controlled Oral Word Association Test (COWAT)
Bethesda Eye and Attention Measure (BEAM)
2,113 studies on the registry are indexed under Brain Injuries; 384 are open to participants now.
This study's enrollment of 37 is below the median of 48 across 1,331 interventional studies indexed under Brain Injuries.
Browse Brain Injuries studies →National Institutes of Health Clinical Center (CC) is the lead sponsor of 367 studies on the registry; 27 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 18 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects eligible for participation must meet the following criteria:
EXCLUSION CRITERIA:
Subjects are not eligible for participation if any of the following conditions exist:
Risk for injury from the MRI magnet, including:
To verify this information, study coordinators will request medical records (i.e., recent medical history, medication list, any neuroimaging, and records pertinent to the participant s recent injury) to further evaluate potential participants inclusion into the study. Medical records can be obtained in three ways:
Medical history data will be reviewed, and if it is clear that the patient does not meet the inclusion criteria, we will contact them and cancel their appointment. Data obtained in this manner may be used to evaluate participant eligibility; however, it will not be used for any research purposes. Additionally, for any patients who are deemed not eligible to participate, their medical history data will be destroyed in accordance with NIH regulations.
As a condition of receiving funding from CNRM, de-identified imaging and phenotyping data (i.e., neurocognitive test results and behavioral questionnaires) from funded studies must be made available within a centralized repository (the CNRM Informatics Core) one year after the completion of the study. This is intended to facilitate use and analysis of this data for future research questions or projects. As such, potential subjects will be informed that they should not participate in this study if they do not want their data used for other projects.
Immediate Intervention
Behavioral: VR Driving
Wait list
Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
VR Driving, Cognitive test, and Symptoms
-Results from the Virtual Reality Driving Assessment (baseline and post- intervention Tactical scenario composite scores)-Total scores on the Neurobehavioral Symptom Inventory-Standard and scaled scores from the following cognitive assessments (from the TBI Common Data Elements identified by NINDS):--WAIS-IV Digit Span subtest--WAIS-IV Digit-Symbol--Coding subtest
Time frame: pre/post after 16 weeks of intervention
MRI, Phenotyping, & Driving evals
Time frame: Ongoing
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institutes of Health Clinical Center (CC)